Amgen 2025 Q3 Earnings Beats Expectations with 13.6% Net Income Growth

Amgen (AMGN) reported Q3 2025 earnings with a 12.1% revenue increase to $9.14 billion and a 13.5% rise in EPS to $5.98, surpassing expectations. , aligning with Q3 results.

Revenue

, driven by robust performance across key therapies. , , respectively. . Other notable segments included Otezla ($585 million), , and Nplate ($457 million). The company also reported $420 million in other revenues, .

Earnings/Net Income

, with net income reaching $3.22 billion—a 13.6% increase from $2.83 billion in 2024 Q3. The EPS growth reflects strong operational efficiency and pricing resilience.

Price Action

Post-earnings, AMGN shares rose 5.52% in the latest trading day, , and 8.75% month-to-date, outperforming broader market trends.

Post-Earnings Price Action Review

, . Analysts highlighted the company’s strategic investments in manufacturing and its resilient portfolio. .

CEO Commentary

CEO Robert A. Bradway emphasized Amgen’s resilience in navigating market dynamics, crediting growth in oncology and inflammation therapies. He acknowledged pricing pressures and competitive challenges but underscored confidence in R&D investments and global market access expansion.

Guidance

, with Q3 results aligning to the upper end of these ranges. .

Additional News

, , . Institutional investors, including NewSquare Capital and First Horizon Advisors, adjusted holdings, . , . , .

, supported by a diversified product portfolio and strategic capital allocation.